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Objectives: To synthesize magnetic particles of lanthanum-strontium manganite,    prepare the magnetic fluid (MF), evaluate 
the generation of heat by particles and determine their common toxiсity. Methods: Nanoparticles based on the solid solutions 
of lanthanum-strontium manganite (La1-xSrxMnO3) have been synthesized by a sol-gel method. Conventional methods of experi-
mental oncology were used.  Results:  Nanoparticles of ferromagnetic materials on the basis of solid solutions of lanthanum stron-
tium manganite by sol-gel method were synthesized. It was shown the possibility to regulate the aggregate form of particles that 
are formed during the synthesis. Magnetic fluid based on the synthesized nanoparticles and water solutions of agarose have been 
produced. It was shown the possibility to heat this magnetic fluid up to 42–45 °С in externally applied alternating magnetic field 
(AMF) operated at 100–400 kHz. It was determined that under long-term influence of AMF nanofluid is heated up to temperature 
which is not over that of magnetic phase transition.  It was detected that magnetic powder as well as fluid have not displayed acute 
toxicity or side effects (intraperitoneal or intratumoral administration) in animals either intact or with transplanted tumors. Con-
clusions: Possibility of synthesized magnetic fluid to generate heat in externally applied AMF as well as lack of  side effects allow 
to consider its as a potential mean for tumor hyperthermia (HT). 
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Hyperthermia (HT) is applied in combination with 
radiation and/or chemotherapy in the treatment of pa-
tients with severe malignant tumors more than 30 years 
demonstrating significantly enhancement of therapy 
outcome [1–5]. At the same time, some of the basic 
problems of HT, in particular receiving the homoge-
neous distribution of temperature in tumor volume and 
heating the deep-seated tumors are not resolved till 
now despite of intensive efforts in the field of technical 
arrangement of clinical HT.
Among the different approaches to overcome 
above mentioned problems and enhance the HT ef-
ficacy the nanotechnology seems to be the most prom-
ising. At the present time the studies dedicated to the 
synthesis of magnetic nanoparticles for the biomedical 
applications are became the more and more intensive. 
Organic and inorganic nanoparticles are widely used 
in the diagnostics and treatment of various diseases, 
in particular neoplastic one [6–8]. Special inter-
est is focused on the ferromagnetic nanoparticles 
that can be heated by externally applied alternating 
magnetic field resulting in the heating of tumor tissue 
[9–11]. It was shown that the application of magnetic 
nanoparticles in the combined cancer treatment allows 
to enhance the therapy efficacy [12–17].
Up to date, the most common magnetic materials 
for tumor hyperthermia as well as for drug delivery 
are magnetite (Fe3O4) and maghemite (γ-Fe2O3) the 
biocompatibility of which are well known [11, 18, 19].
It has to be mentioned that the highest achieve-
ments in the field of nanohyperthermia were received 
by Jordan et al. [13, 15, 16]. They have elaborated the 
method of local heating of tumor by means of magnetic 
fluid (Fe3O4 particles with 15–20 nm in size) that was 
injected into the tumor followed by exposition of tumor 
to an alternating magnetic field (100 kHz frequency) 
that resulted in the increase of tumor temperature 
up to 44–45 °C. The coating of nanoparticles by amino-
sylane forms the preventive “sleeve” around the core 
of iron oxide that helps to particles to be absorbed 
by tumor cells in more significant amount and to avoid 
the withdrawal from tumor [11, 17].
It has to be noted that one problem is discussed now 
very actively, namely the possible negative influence 
of ferromagnetic materials with high Curie temperature 
on hyperthermic procedure, in particular excessive 
heating of surrounding healthy tissues and other side 
effects by the exploitation of the following nanopar-
ticles: Fe3O4 (585 °C), γ-Fe2O3 (447 °C), CoFe2O4 (518 °C), 
ZnFe2O4 (545 °C) and BaFe12O19 (580 °C) [20, 21].
Nanoparticles with the phase transition in the 
temperature range 42–45 °C that are optimal for the 
destruction of malignant tumors, may be exploited 
as safety alternative for tumor HT. The heterosub-
situte lanthanum-strontium manganites were con-
sidered as a very promising to achieve this aim: 
La1-xAxMnO3 (where A = Ag, Ba, Ca, Na, Sr) [22–25]. 
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These substances demonstrate the ferromagnetic 
effect in the range of x=0.25–0.5 with Curie point = 
0–95 °C.  
On the current days there is a large number 
of methods for nanosized  ferromagnetic materials 
preparation. One of the promising methods is a sol-
gel method, the use of which can produce crystal 
nanoparticles and decrease the temperature of the 
single-phase product synthesis. 
Moreover, there is very important to create on the 
basis of ferromagnetic nanoparticles the magnetic flu-
ids (MF) which could be heated by the exposition to AMF 
and characterized by high level of biocompatibility. 
The current study was aimed to synthesize magnet-
ic particles of lanthanum-strontium manganite, evalu-
ate structural and electrical properties of nanosized 
particles, create the ferromagnetic fluid, determine 
their heating by AMF, and assess  of MF toxicity in vivo. 
MATERIALS AND METHODS
Synthesis of nanoparticles. Samples of the solid 
solution La1-xSrxMnO3 (xSr = 0.225–0.3), have been syn-
thesized by the sol-gel method [26, 27]. Water-soluble 
salts La(NO3)3, Sr(NO3)2, Mn(NO3)2 were used as start-
ing reagents. Calculated amounts of reagents were 
dissolved in distilled water. Citric acid and ethylene 
glycol as gelling additives were added to the solution. 
When the mixture is heated at 80 °C, polyesterifica-
tion occurs with the formation of polymeric gel. Then 
the temperature increased up to 200 °C, and powder 
of La1-xSrxMnO3 precursor was formed as a result 
of pyrolysis. Heat treatment of obtained powders of 
“precursor” was performed in the temperature range 
400–1100 °C in a crucible from Al2O3 in the air for 2–4 h. 
For comparison, the control samples have been also 
synthesized by the method of solid state reactions and 
by precipitation from solution. Synthesis of samples 
by solid-state reactions were carried out as described 
in [28]. Synthesis of the samples by precipitation from 
solution was carried out as described in [29]. 
Physic-technical methods. X-ray diffraction 
(XRD) measurements were carried out on a “DRON-
4–07” diffractometer (CuKα radiation) in the range 
of 2θ = 10–150 °C. 
Alternating magnetic field. A high frequency gen-
erator produced by Institute of Electrodynamics was 
used to induce an alternating current of 70 A at a fre-
quency of 100–440 kHz. The equipment is shown 
in Fig. 1. The current passes through a custom-made 
five-turn water-cooled coil of 30 mm in internal di-
ameter and 30 mm in height to generate a magnetic 
field inside the coil. The electromagnetic field within 
this coil is not uniform. The sample with magnetic 
fluid was placed on a platform in a center inside the 
coil with maximum magnetic field strength above 
7.7 kA/m (Fig. 2, a, 2, b, and 2, c). According to the 
heating mechanisms of nanoparticle hyperthermia, 
the induced energy generation rate is approximately 
proportional to H2. But a characteristic size of the 
sample was relatively small (8 mm in diameter and 
15 mm in height), and a variation of the magnetic field 
inside the whole sample can be considered negligible. 
Fig. 1. Experimental setup consisting of a high frequency gen-
erator (a) and coil (b)
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Fig. 2. Distribution of magnetic field |H| in the coil (a) and 
magnetic field HZ on the vertical (b) and horizontal  (c) axis 
of symmetry
Temperature measurement. The temperature 
monitored by fine thermocouple (copper-constantan) 
were recorded every 60 s during the entire experiment. 
At this moment the high frequency generator was turn 
off at a small interval  of time ~5 s.
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Biological studies. In accordance with the meth-
odological instructions the normal animals have been 
used in this study. The experiments were conducted 
with intact С57Bl/6 mice (bred of Institute of Experi-
mental Pathology, Oncology and Radiobiology), males 
with body weight of 20–22 g. There were 6 animals 
in each experimental group. It was used 30 normal 
mice to determine the acute toxicity, 8 Lewis lung 
carcinoma-bearing mice (C57Bl/6, male, 20–22 g, 
intramuscular transplantation) and 15 Guerin carcino-
ma-bearing rats (IEPOR bred, female, 170–200 g, sub-
cutaneous translpantation). All experiments had been 
approved by the regional animal ethics committee. 
RESULTS AND DISCUSSION
According to the method of sol-gel synthesis, 
the addition of gel-forming substances to the salts 
of metals and subsequent heating results in the series 
of processes in solution, in particular the formation 
of heteronuclear metal complexes with citric acid 
as well as citric acid polymerization with ethylene 
glycol described in the literature [27, 30, 31]. The 
polymerization of the gel was carried out at different 
pH. The solution of ammonia was added into obtained 
gel to change pH with the following evaporation of so-
lutions to obtain a powder “precursor”. The powders 
obtained at different pH and temperatures of heat-
treatment were investigated by X-ray and electron 
microscopy (Fig. 3 and 4). 
As shown in Fig. 3, a, the broad halo in the field 
of 2θ = 20–25° is observed for the powder “precursor” 
synthesized in acidic environment (pH = 1.5) at 400 °C, 
that indicates its amorphous state. Further heat-treat-
ment leads to the crystallization of the sample that was 
initiated in the temperature range of 500–600 °C. After 
heat treatment at 800 °C the sample is a single phased 
according to X-ray analysis, but a slight broadening 
of the main peaks were observed on X-ray slides. At the 
same time, according to electron microscopic studies 
(Fig. 4, a), the investigated particles have amorphous 
and crystalline regions, that is also confirmed by elec-
tron diffraction analysis. After analyzing the results 
of electron diffraction of amorphous particles as well 
as X-ray data it was concluded that the amorphous 
regions, which are observed in the agglomerates are 
carbon that is not oxidized during the pyrolysis of gel. 
Detailed microstructural analysis of crystalline par-
ticles showed that their sizes are within 20–50 nm. The 
particles form dense agglomerates with size ranged 
500–2000 nm. 
According to X-ray analysis for samples obtained 
at a pH of the gel, equal to 6 (Fig. 3, b), after heat treat-
ment at 400 °C there is a somewhat different picture, 
namely, the samples are partially amorphous and 
partially crystalline, as evidenced by an amorphous 
halo in the field of 2θ = 20–25 °C, as well as the  pres-
ence of broad peaks, indicating the beginning of the 
formation of crystalline compounds. 
The micrographs and electron diffraction data for 
solid solution La0.775Sr0,225MnO3, synthesized at pH 
= 6 after heat treatment at 800 °C were presented 
on Fig. 4, b. For this sample, the formation of agglomer-
ates consisting from smaller units, occurs which, in turn, 
are formed from the nanoparticles. These agglomerates 
are formed by the crystal particles and have not the 
amorphous phase, unlike the previous model. As seen 
from the microphotograhs, the size of the particles that 
form the agglomerates is 50–70 nm.  
The X-ray powder diffraction patterns of samples 
obtained at gel pH=9 (Fig. 3, c) after heat treatment 
contain only crystalline particles. X-ray peaks are nar-
row, indicating a high degree of sample crystallinity. For 
a solid solution La0.775Sr0,225MnO3, synthesized at pH = 
9, after heat treatment at 800 °C, the formation of “soft” 
slightly-agglomerated powders with a loose structure 
of the agglomerates, in which the particles have a size 
of about 40–50 nm (Fig. 4, c) was observed. In this case, 
as seen from the figure, the particles are fully crystal. 
In accordance with Brinker and Scherer, and Kabi-
hana [31, 32], observed pH influence is associated with 
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Fig. 3. X-ray patterns of precursor for receiving of solid solution 
La0.775Sr 0,225MnO3 after thermotreatment at different temperature: 
400 °С (1); 600 °С (2); 800 °С (3). Gel pH ~ 1.5 (a), 6 (b), 9 (c)
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the fact that the formation of metal complexes with citric 
acid and their subsequent polymerization with ethylene 
glycol under acidic environment (pH=1.5) was occurred. 
Under alkaline environment (pH=9), the formation of hy-
droxides of metals and their interaction with the polymer 
gel is caused by the formation of hydrogen bonds. 
It should be noted that the formation of single-
phased crystal structure by using the method of solid 
state reactions occurs in the temperature range 
1000–1150 °C while the precipitation from solutions the 
single-phase crystalline structure is formed at 1350 °C, 
which is consistent with Belous et al. [29]. 
Our studies have shown that using the proposed 
method of sol-gel synthesis of solid solutions of the 
system  La0.775Sr0.225MnO3 the single-phased crystal 
structure begins to be formed at 500–600 °C, and 
at 800 °C the samples are fully crystal (Table). The 
particle size is about 40–50 nm. On the basis of syn-
thesized nanoparticles La0.775Sr0.225MnO3 the magnetic 
fluid was obtained where the aqueous solutions of aga-
rose as gel-forming component was used.
The results of investigations of “agarose” aqueous 
solution viscosity and the maximum permissible viscos-
ity of fluids in living organisms have shown in Fig. 5 [33]. 
It was concluded that the optimum concentration of base 
material (agarose) should not exceed 0.06%. The mag-
netic particles of a solid solution of La0.775Sr0.225MnO3, 
synthesized both by solid state reaction method and 
sol-gel method with different temperatures of heat-
treatment (Tterm = 800, 900, 1000, 1100, 1150°C) were 
used to evaluate the influence of magnetic properties 
of the substance on magnetic fluid heating. 
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Fig. 5. Dependence of gel viscosity prepared by means of aga-
rose on the basic substance concentration
Table. Phase composition of manganites La0.775Sr0.225MnO3 powders according to conditions of synthesis and thermotreatment temperature*
Т, К Solid phase synthesis Synthesis by precipitation from solutions Sol-gel synthesis
870 Mn2O3(100), La2O3(78), SrCO3(57), La(OH)3(32),** SrO(32), P(8), 
SrMnO3(8)
P(100), La2O2CO3(44), Sr2MnO5(32), Sr2MnO4(16), Mn2O3(14), 
SrCO3(3)
P(100)
970 Mn2O3(100), La2O3(78), SrCO3(57), La(OH)3(32),** SrO(32), P(8), 
SrMnO3(8)
P(100), La2O2CO3(44), Sr2MnO5(32), Sr2MnO4(16), Mn2O3(14), 
SrCO3(3)
P(100)
1070 La2O3(100), Mn2O3(97), P(72), a-SrMnO3(13) P(100), Sr2Mn2O5(12),  La(OH)3(11), Mn2O3(9), (La1-ySry)2MnO4(7), 
La2O2CO3(5)
P(100)
1170 P(100), Mn2O3(33), La(OH)3(14), a-SrMnO3(5), SrCO3(3), SrO(3) P(100), Sr2Mn2O5(7),  La(OH)3(4), (La1-ySry)2MnO4(4), La2O2CO3(1) P(100)
1270 P(100), La2O3(11), a-SrMnO3(3), Mn3O4(1.5) P(100), Sr2Mn2O5(4), (La1-ySry)2MnO4(2), La2O2CO3(0.7) P(100)
1320 P(100), La2O3 (traces) – P(100)
1370 P(100) P(100), Sr2Mn2O5(4), (La1-ySry)2MnO4(1.7), La2O2CO3(0.6) P(100)
1570 P(100) P(100), (La1-ySry)2MnO4(1), La2O2CO3(traces) P(100)
1620 P(100) P(100) P(100)
*Numbers in parentheses — relative intensity of most reflexes in corresponding phases (%); 
**Appearance of La(OH)3 is caused by La2O3 absorption of water from air under storage; P — perovskite.
b
c
Crystalline
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Amorphous
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a
Fig. 4. Microphotographs of particles of solid solution 
La0.775Sr0,0225MnO3 synthesized at 800 °C during 2 h. Gel pH 
~ 1,5 (a), 6 (b), 9(c)
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AMF resting. The heating of magnetic fluids were 
carried out in an alternating magnetic field in the 
frequency range of 100–400 kHz. It was determined 
that the heating of magnetic fluids of all prepared 
samples to a constant temperature was observed 
during 20 minutes (Fig. 6). It was also shown that the 
temperature of the synthesis of magnetic particles 
impact on the heating temperature of magnetic fluids. 
This regularity can be explained by changes in the 
ratio Mn3+/Mn4+ [34–36], which results in the change 
of Curie tempe rature and conductivity as well as par-
ticle sizes [37]. The dependence of the magnetization 
of La0.775Sr0.225MnO3, synthesized by sol-gel method 
at pH = 9, from the magnetic field parameters was 
evaluated. It was found that the coercitive force of this 
powder (Hc) is 2834.39 A/m, and the magnetization 
(Ms) is 4.79 Gc cm3/g, whereas the theoretical Ms for 
its is 91.5 Gc cm3/g.  
Toxicity of magnetic fluid. It was determined the 
maximal tolerable dose (MTD) in accordance with in-
structions. Conventional indices of acute toxicity, such 
as LD10, LD50, LD100 could not been determined be-
cause of low toxicity of tested substance that resulted 
in the necessity to apply of overdoses of nanopowder. 
МTD was determined as a dose that does not results 
in  the  death of no one animal in the group and at the 
same time does not provoke body weight loss not 
more than 10%. The substance that results in the body 
weight loss more than 10% is considered toxic. In order 
to designate the toxicity of the substance each animal 
was weighed before it administration and every day 
after up to the end of experiment. 
0 5 10 15 20 25
65
60
55
50
45
40
35
30
25
t, min
f = 300 kHz
T,
 °C
Fig. 6. Time-dependent heating of MF, based on agarose 
and La0.775Sr0.225MnO3, induced with AMF (300 kHz, strength 
of 7.1 kA/m). 1, 2 — the samples were synthesized by the method 
of solid-phase reaction at 1200 and 1150 0C, respectively; 3, 4, 
5, 6 — the samples were synthesized by sol-gel method at 900, 
800, 1000 and 1100 0C, respectively. The shaded area indicates 
the optimal temperature for tumor hyperthermia
Magnetic fluid (sol-gel method, Tterm = 800 °C) 
was administered into the mice at the doses of 100, 
200, 300 and 400 mg of powder of nanoparticles/
kg of body weight. It was given intraperitoneally, 
in a single dose. Duration of observation under every 
group was 14 days. 
Under the administration of this substance at the 
doses of 50 and 100 mg/kg body weight loss was not 
observed on the 1st day after. On the contrary it was 
observed body weight increase gradually up to the end 
of experiment and approximately on 26±3.0% more 
that it was before  substance administration.
Beginning from a dose of 200 mg/kg it was ob-
served inconsequential body weight loss on the 1st 
day after injection — by 1.6±0.4% compare with 
the initial ones and than body weight loss increased 
with the increase of doses administered: at a dose 
of 300 mg/kg — by 7.5±1.5%, at a dose of 400 mg/
kg — by 8.5±2.1%.
At a dose of 200 mg/kg as early as on the 4th day 
after injection it was observed that body weight was 
not only restored but it was going on gradual increasing 
by 25±2.1% up to the end of experiment.
At a dose of 300 mg/kg rather substantial body 
weight loss 7.5±1.5% was registered already on the 
1st day after. On the 2nd and 3rd days animal body 
weight started to restore gradually but not substan-
tial: by 2.45±0.9% and by 2.1±0.6%, respectively. 
Beginning from the 4th day after injection body weight 
of almost all  mice returned to the initial level and then 
started to be increased by 6.8±0.5% and 9.1±1.8% 
on the 4th and 7th days, respectively.
Dose of 400 mg/kg of body weight caused the most 
substantial body weight loss by 8.5 ±2.3% on the 1st 
day after injection and continue to be observed on the 
2nd, 3rd and 4th day: by 5.3±2.1%, 2.3 ±1.7% and 
1.6 ±0.7%, respectively, in comparison  with initial body 
weight of the mice. In further it was observed that body 
weight loss gradually started to delay and beginning 
from the 7th day mice body weight was increased 
by 3.3±1.1% and at the end of the experiment (at the 
14th day) it was 5.6±2.8% higher.
On the grounds of the obtained results it was pos-
sible to make the conclusion that maximum tolerable 
dose (MTD) is 300 mg/kg of body weight.
In conclusion, the nanoparticles of a solid solu-
tion La0.775Sr0.225MnO3 produced by sol-gel method 
was synthesized and magnetic fluid on their basis 
prepared. It was shown the possibility to control the 
size and aggregate state of particles by changing the 
synthesis conditions. The physical parameters of the 
synthesized nanoparticles were evaluated, and it was 
shown the change of the phase transition temperature 
from ferromagnetic to paramagnetic state for the 
synthesized nanoparticles. The possibility to heat the 
magnetic fluid obtained on the basis of mentioned 
nanoparticles up to 42–45 °C in an alternating mag-
netic field was demonstrated. It was also established 
that the temperature of heated fluid was not exceeded 
the temperature of magnetic phase transition under 
prolonged exposure to AMF.
It was determined that synthesized nanoparticles 
of lanthanum strontium manganite (La 0.775Sr0.225MnO3) 
did not display the toxicity or provoked the side effects 
being administered intraperitoneally into the experi-
mental animals neither intact nor with transplanted 
tumors. Maximum tolerable dose (MTD) of nanopow-
der is 300 mg/kg of body weight.
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